Slide 1: Biogen Idec R&D Strategy
Biogen Idec R&D Strategy Cecil B. Pickett, PhD President, Research & Development March 25, 2009
Slide 2: Forward Looking Statements and Important Information
Forward Looking Statements and Important Information This presentation includes forward-looking statements about: - estimates of the market potential for our product candidates - our expected filings with regulatory agencies - the anticipated development and timing of programs in our clinical pipeli
Slide 3: Biogen Idec R&D Strengths
Biogen Idec R&D Strengths Strong R&D fundamentals World class biotherapeutic discovery and development organization Focused drug discovery and development efforts Neurology Immunology Oncology Cardiology Strong link between discovery research, clinical development, and strategic business units Prove
Slide 4: R&D Strategy
R&D Strategy Preclinical Proof-of- Concept Registration & Filing First-in-Human 5 programs 13 programs 7 programs 20 programs Focus on novel therapeutics to address areas of high unmet medical need Internal discoveries and in- licensing opportunities First-in-Class molecules as well as Best-in-Class
Slide 5: Goal of Strong Growth in Registrational Programs
Goal of Strong Growth in Registrational Programs BG-12 MS Galiximab Lumiliximab Lixivaptan - Hyponatremia Ocrelizumab RA BG-12 MS Galiximab Lumiliximab Lixivaptan - Hyponatremia Ocrelizumab RA ADENTRI(r) IV BG-12 MS Galiximab Lumiliximab Lixivaptan - Hyponatremia Ocrelizumab RA ADENTRI IV PEG-IFN BG
Slide 6: Independent Assessment by Moody's - Highest Quality Late Stage Pipeline
Independent Assessment by Moody's - Highest Quality Late Stage Pipeline Moody's Investors Service research Issuer Scorecard: Large U.S. Pharmaceutical Companies published February 2009 Most recent rating methodology mapping for 12 large U.S.-based pharmaceutical and biotech companies Ranking of the
Slide 7: Delivering Data Readouts and Decision Points
H2 2007 H1 2008 H2 2008 Daclizumab in RRMS - Ph2 (CHOICE) Baminercept in RA - Ph2a RITUXAN in SLE - Ph2/3 RITUXAN(r) in DMARD-IR RA - Ph3 RITUXAN in PPMS - Ph3 BIIB14 in PD - Ph2a Hsp90i in GIST - Ph2a Volociximab in Ovarian - Ph2 RITUXAN in DMARD-naive RA - Ph3 RITUXAN in CLL - Ph3 Positive Readout
Slide 8: Patents and Publications
14 Patents and Publications Recent Patents 5,763 Total Biogen Idec Patents Total Issued WW (approx.) Total Pending WW (approx.) 2,877 2,886 2008 Publications 89 Peer Reviewed Publications in 2008 Clinical Publications 38 Immunology 34 Neurology 22 Oncology 13 Cardiovascular 12 Hematology 7 0 100 200
Slide 9: R&D Organization Summary
R&D Organization Summary Outstanding people at all levels in the R&D Organization Robust pipeline with important compounds at all stages of development World-class expertise in discovery and development of biologics Focus on executing clinical trials Continue developing compounds in registrational p
Slide 10: Biogen Idec Pipeline Summary
Biogen Idec Pipeline Summary Cecil B. Pickett, PhD President, Research & Development March 25, 2009
Slide 11: Robust Pipeline - Late, Early, Discovery
Robust Pipeline - Late, Early, Discovery Product pipeline significantly strengthened over past three years More than 20 programs added to the clinical pipeline or advanced to next clinical step since the start of 2007 More than ten molecules accessed via business development strategy 60 clinical tri
Slide 12: Late Stage Pipeline
Neurology Oncology Cardiopulmonary & Emerging Areas Immunology 14 AVONEX TYSABRI BG-12 Daclizumab Multiple sclerosis Multiple sclerosis Multiple sclerosis Multiple sclerosis Pre-Clinical Phase 1 Phase 2 Phase 3 Market RITUXAN FUMADERM(r) TYSABRI RITUXAN Ocrelizumab Rheumatoid arthritis Psoriasis Cro
Slide 13: Early Stage Pipeline: 20 Programs in Phase 2 and Beyond
Oncology Cardiopulmonary & Emerging Areas Immunology Neurology 14 Ocrelizumab CDP323 BIIB014 PEGylated-IFN^1a Neublastin Anti-LINGO-1 S1P agonist Multiple sclerosis Multiple sclerosis Parkinson's Multiple sclerosis Pain MS MS Pre-Clinical Phase 1 Phase 2 Phase 3 Market AVONEX BG-12 Anti-TWEAK Anti-C
Slide 14: Biogen Idec Research & Development Day
Biogen Idec Research & Development Day March 25, 2009